SG11201811719RA - Conjugates for targeted cell surface editing - Google Patents

Conjugates for targeted cell surface editing

Info

Publication number
SG11201811719RA
SG11201811719RA SG11201811719RA SG11201811719RA SG11201811719RA SG 11201811719R A SG11201811719R A SG 11201811719RA SG 11201811719R A SG11201811719R A SG 11201811719RA SG 11201811719R A SG11201811719R A SG 11201811719RA SG 11201811719R A SG11201811719R A SG 11201811719RA
Authority
SG
Singapore
Prior art keywords
international
stanford
california
conjugates
cell surface
Prior art date
Application number
SG11201811719RA
Other languages
English (en)
Inventor
Elliot C Woods
Han Xiao
Carolyn R Bertozzi
Melissa Gray
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Publication of SG11201811719RA publication Critical patent/SG11201811719RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6815—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01018—Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11201811719RA 2016-07-01 2017-06-30 Conjugates for targeted cell surface editing SG11201811719RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662357645P 2016-07-01 2016-07-01
PCT/US2017/040411 WO2018006034A1 (en) 2016-07-01 2017-06-30 Conjugates for targeted cell surface editing

Publications (1)

Publication Number Publication Date
SG11201811719RA true SG11201811719RA (en) 2019-01-30

Family

ID=60787043

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201811719RA SG11201811719RA (en) 2016-07-01 2017-06-30 Conjugates for targeted cell surface editing

Country Status (14)

Country Link
US (2) US11459398B2 (es)
EP (2) EP4218802A3 (es)
JP (2) JP7187024B2 (es)
KR (2) KR20230142631A (es)
CN (1) CN109641038A (es)
AU (2) AU2017290554B2 (es)
BR (1) BR112018077362A2 (es)
CA (1) CA3027234A1 (es)
DK (1) DK3478314T5 (es)
ES (1) ES2947312T3 (es)
IL (2) IL263617B2 (es)
MX (1) MX2018016393A (es)
SG (1) SG11201811719RA (es)
WO (1) WO2018006034A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7525980B2 (ja) 2015-08-28 2024-07-31 アレクトル エルエルシー 抗Ｓｉｇｌｅｃ－７抗体及びその使用方法
GB201616006D0 (en) * 2016-09-20 2016-11-02 Univ Court Of The Univ Of St Andrews The Cell modulation
WO2018231661A1 (en) * 2017-06-12 2018-12-20 Tianxin Wang Methods and reagents to treat tumor and cancer
AU2019205912A1 (en) 2018-01-03 2020-07-16 Palleon Pharmaceuticals Inc. Recombinant human sialidases, sialidase fusion proteins, and methods of using the same
JP7562421B2 (ja) * 2018-06-07 2024-10-07 パレオン ファーマシューティカルズ インコーポレイテッド 炭水化物を検出するためおよび／またはシグレック媒介障害を治療するための多量体タンパク質
CN112512638A (zh) * 2018-06-08 2021-03-16 艾利妥 抗siglec-7抗体及其使用方法
GB201811291D0 (en) * 2018-07-10 2018-08-29 Univ Dublin City A method of predicting response to treatment in cancer patients
EP3604551A1 (en) * 2018-07-31 2020-02-05 Université de Bretagne Occidentale Complement-dependent cytotoxicity and sialylation as biomarkers for predicting clinical response to cancer treatment with antibody or derivative mediating complement activation
GB201819920D0 (en) * 2018-12-06 2019-01-23 Pneumagen Ltd Cancer treatment
WO2020142727A1 (en) * 2019-01-03 2020-07-09 Palleon Pharmaceuticals Inc. Methods and compositions for treating cancer with immune cells
WO2020172072A1 (en) * 2019-02-21 2020-08-27 The General Hospital Corporation Glycoengineering immunoglobulin e
WO2021003464A1 (en) * 2019-07-03 2021-01-07 Palleon Pharmaceuticals Inc. Sialidase-pd-l1-antibody fusion proteins and methods of use thereof
WO2021003468A2 (en) * 2019-07-03 2021-01-07 Palleon Pharmaceuticals Inc. Recombinant sialidases and methods of using the same
CN114302897A (zh) * 2019-07-03 2022-04-08 帕利昂制药有限公司 唾液酸酶-her2抗体融合蛋白及其使用方法
US20220380742A1 (en) * 2019-07-03 2022-12-01 Palleon Pharmaceuticals Inc. Sialidase-cd20-antibody fusion proteins and methods of use thereof
WO2021003469A2 (en) * 2019-07-03 2021-01-07 Palleon Pharmaceuticals Inc. Recombinant human sialidases, sialidase fusion proteins, and methods of using the same
US20230293711A1 (en) * 2020-07-21 2023-09-21 The Scripps Research Institute Disruption of cd28-sialoside ligand complexes to enhance t cell activation
CA3200768A1 (en) * 2020-12-04 2022-06-09 Scott Hilderbrand Antibody-oligonucleotide complexes and uses thereof
TW202304472A (zh) 2021-04-23 2023-02-01 美商格納生物公司 經聚醣修飾之核酸、製備方法及治療用途
WO2023129822A2 (en) * 2021-12-28 2023-07-06 The Board Of Trustees Of The Leland Stanford Junior University Chemically modified bacterial peptidoglycan compositions and uses thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2620649C3 (de) 1976-05-11 1980-11-06 Behringwerke Ag, 3550 Marburg Immunologisches Adjuvans
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
FR2828386B1 (fr) 2001-08-10 2004-06-11 Jean Noel Acquaviva Ecran de vision coupe-vent
US8512710B2 (en) 2002-11-22 2013-08-20 Ansun Biopharma, Inc. Class of therapeutic protein based molecules
US7807174B2 (en) 2002-11-22 2010-10-05 Nexbio, Inc. Class of therapeutic protein based molecules
EP1567185B1 (en) 2002-11-22 2020-02-19 Ansun Biopharma, Inc. Broad spectrum anti-viral therapeutics and prophylaxis
CN104758253A (zh) 2006-01-24 2015-07-08 安迅生物制药公司 大分子微球的制备技术
MX2008012013A (es) * 2006-03-23 2008-10-03 Novartis Ag Tratamiento con anticuerpo antigeno de celulas neoplasicas.
EP1938835A1 (en) 2006-12-29 2008-07-02 Pevion Biotech AG Non-specific immunostimulating agents
US8398971B2 (en) 2009-11-06 2013-03-19 Nexbio, Inc. Methods, compounds, and compositions for treatment and prophylaxis in the respiratory tract
AU2013274078A1 (en) * 2012-06-14 2015-01-29 Ambrx, Inc. Anti-PSMA antibodies conjugated to nuclear receptor ligand polypeptides
CN112587658A (zh) * 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
UA105278C2 (ru) * 2012-09-06 2014-04-25 Інститут Біології Клітини Нан України Способ получения каталитически активных антител (абзимов) с сиалидазной активностью
CN110295114A (zh) 2013-03-15 2019-10-01 安迅生物制药公司 蛋白纯化的新颖方法
WO2014201034A2 (en) 2013-06-10 2014-12-18 Ansun Biopharma, Inc. Treatment for polyomavirus infection
WO2014201027A2 (en) 2013-06-10 2014-12-18 Ansun Biopharma, Inc. Treatment of merkel cell polyomavirus infection
US20170165334A1 (en) 2015-12-11 2017-06-15 Tianxin Wang Methods to Treat Diseases with Protein, Peptide, Antigen Modification and Hemopurification
WO2015184356A1 (en) 2014-05-30 2015-12-03 Ansun Biopharma, Inc. Treatment of middle east respiratory syndrome coronavirus
DK3191517T3 (da) * 2014-09-10 2021-01-25 Innate Pharma Krydsreaktive siglec-antistoffer
WO2016044656A1 (en) 2014-09-17 2016-03-24 Ansun Biopharma, Inc. Treatment of infection by human enterovirus d68
WO2016200916A1 (en) 2015-06-08 2016-12-15 Ansun Biopharma, Inc. Treatment of human metapneumovirus
AR107483A1 (es) 2016-01-29 2018-05-02 Hanmi Pharm Ind Co Ltd Conjugado de enzimas terapéuticas
US20180271997A1 (en) 2016-05-31 2018-09-27 Tianxin Wang Methods and Reagents to Treat Tumor and Cancer
GB201616006D0 (en) 2016-09-20 2016-11-02 Univ Court Of The Univ Of St Andrews The Cell modulation
KR102471458B1 (ko) 2016-12-28 2022-11-25 제이씨알 파마 가부시키가이샤 동결건조 제제
WO2018231661A1 (en) 2017-06-12 2018-12-20 Tianxin Wang Methods and reagents to treat tumor and cancer
CN112739374A (zh) 2018-07-20 2021-04-30 安迅生物制药公司 唾液酸酶向癌细胞、免疫细胞和肿瘤微环境的递送

Also Published As

Publication number Publication date
MX2018016393A (es) 2019-08-12
ES2947312T3 (es) 2023-08-04
EP4218802A3 (en) 2023-09-27
AU2017290554A1 (en) 2019-01-17
US11459398B2 (en) 2022-10-04
DK3478314T3 (da) 2023-06-19
IL305907A (en) 2023-11-01
CA3027234A1 (en) 2018-01-04
CN109641038A (zh) 2019-04-16
JP7496629B2 (ja) 2024-06-07
JP7187024B2 (ja) 2022-12-12
IL263617B1 (en) 2023-10-01
AU2020289739A1 (en) 2021-01-21
US20190248919A1 (en) 2019-08-15
JP2019531697A (ja) 2019-11-07
AU2017290554B2 (en) 2020-10-08
WO2018006034A1 (en) 2018-01-04
US20230287140A1 (en) 2023-09-14
JP2022176981A (ja) 2022-11-30
KR20190025925A (ko) 2019-03-12
IL263617B2 (en) 2024-02-01
IL263617A (en) 2019-02-03
DK3478314T5 (da) 2024-07-15
EP4218802A2 (en) 2023-08-02
KR102581747B1 (ko) 2023-09-22
AU2020289739B2 (en) 2024-08-08
NZ749410A (en) 2021-01-29
EP3478314B1 (en) 2023-03-22
EP3478314A1 (en) 2019-05-08
KR20230142631A (ko) 2023-10-11
BR112018077362A2 (pt) 2019-10-01
EP3478314A4 (en) 2020-05-27

Similar Documents

Publication Publication Date Title
SG11201811719RA (en) Conjugates for targeted cell surface editing
SG11201807187XA (en) Binding members to pd-l1
SG11201807301SA (en) Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors
SG11201807252QA (en) Anti-lag-3 antibodies
SG11201804934PA (en) Novel Compounds
SG11201808920RA (en) Genome editing of human neural stem cells using nucleases
SG11201900077QA (en) 1,3-dihydroxy-phenyl derivatives useful as immunomodulators
SG11201901131VA (en) Substituted pyrrolizine compounds and uses thereof
SG11201805300QA (en) Heterocyclic compounds as immunomodulators
SG11201809064QA (en) Chimeric neurotoxins
SG11201807593TA (en) Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
SG11201808762XA (en) Diagnostic methods for patient specific therapeutic decision making in cancer care
SG11201901959YA (en) Modified stem cell memory t cells, methods of making and methods of using same
SG11201810420YA (en) Antibodies to alpha-synuclein and uses thereof
SG11201809499UA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201805680SA (en) Methods and compositions for the treatment of neurologic disease
SG11201907356SA (en) Piperidine-substituted mnk inhibitors and methods related thereto
SG11201407533SA (en) Antiviral compounds
SG11201806485RA (en) Pyrrolobenzodiazepine conjugates
SG11201408237YA (en) Compound as wnt signaling inhibitor, composition, and use thereof
SG11201809594WA (en) Nicotine particles and compositions
SG11201805385QA (en) Bromodomain and extra-terminal protein inhibitor combination therapy
SG11201909807TA (en) Methods of manufacturing of niraparib
SG11201909501TA (en) Personalized 3d neural culture system for generating human oligodendrocytes and studying myelination in vitro
SG11201804774YA (en) Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug nuc-1031